Displaying 25 - 36 of 136
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
5

AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Displaying 25 - 36 of 136